基于 AI 新生抗原预测的个性化肿瘤 mRNA 疫苗，联合免疫检查点抑制剂，已实现 DCR 100%、ORR 71.4% 的突破性疗效 AI neoantigen-based personalized mRNA cancer vaccine combined with immune checkpoint inhibitors — breakthrough efficacy: DCR 100%, ORR 71.4%
符合以下条件的肿瘤患者可申请入组Cancer patients meeting the following criteria may apply
经临床医生评估，预期生存期超过半年的肿瘤患者Cancer patients with clinically assessed life expectancy exceeding six months
可通过手术或穿刺活检获取新鲜肿瘤组织样本，用于个性化新生抗原分析Fresh tumor tissue obtainable via surgery or biopsy for personalized neoantigen analysis
从入组评估到临床观察的完整治疗路径Complete treatment pathway from enrollment to follow-up
携带既往病历及影像资料就诊，由邹晨医生评估是否符合入组条件Visit with medical records for eligibility assessment by Dr. Zou Chen
入院后通过手术或穿刺活检获取新鲜肿瘤组织样本Obtain fresh tumor tissue via surgery or biopsy
对肿瘤组织进行全长翻译组测序和转录组分析，识别肿瘤特异性新生抗原Full-length translatome sequencing and transcriptome analysis to identify tumor-specific neoantigens
AI 平台预测最优新生抗原组合，设计个性化 mRNA 疫苗序列AI predicts optimal neoantigen combinations and designs personalized vaccine sequences
GMP 体系下完成个性化 mRNA 疫苗的体外转录、LNP 包封及质量检测IVT, LNP encapsulation, and quality control under GMP
联合免疫检查点抑制剂进行 6 次疫苗注射，激活免疫系统精准攻击肿瘤6 injections combined with checkpoint inhibitors to activate immune response
持续 24 个月的临床随访观察，定期评估疗效和安全性24-month follow-up with regular efficacy and safety assessments
南京大学附属苏州医院（苏州市科技城医院）· 邹晨医生Nanjing University Affiliated Suzhou Hospital · Dr. Zou Chen
微信搜索 "南京大学附属苏州医院" 公众号Search "南京大学附属苏州医院" on WeChat
在公众号内选择 预约挂号，搜索医生 邹晨Select Appointment, search Dr. Zou Chen
携带既往病历及影像资料就诊，医生将评估是否符合入组条件Bring medical records and imaging for eligibility assessment
* 本临床试验为研究者发起的临床研究（IIT），免费为符合条件的患者提供个性化肿瘤 mRNA 疫苗治疗。最终入组资格以临床医生评估为准。* This IIT provides personalized mRNA cancer vaccine treatment free of charge. Final eligibility determined by clinical assessment.